资讯

The partnership will give Chugai access to Gero’s artificial intelligence technology to discover novel targets in ...
After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...
Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...
Despite rehiring hundreds of FDA, CDC and NIH employees, the Department of Health and Human Services is still a skeleton of ...
TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...
Slashing adverse drug reactions through pharmacogenetics and advanced AI could help rehabilitate the pharmaceutical ...